The pharmaceutical industry has reportedly reduced its use of anti-competitive agreements since Actavis. This trend will likely push forward as parties involved in reverse payment settlements face litigation threats. Additionally, new and ongoing litigation is expected to surface in relation to pre-Actavis settlement agreements. In this webinar, Dr. Xie and other panelists will discuss the current trends and issues in reverse payment settlements, identify risks and pitfalls, provide an overview of notable cases, and review compliance strategies.